Fact CheckerSign in

NCT07278063Not yet recruiting

Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes

Effect of Gender and Meal Composition on the Postprandial Glycemic Response in People With Type 1 Diabetes: Impact of Fat Content and Menstrual Cycle Phases

Source: ClinicalTrials.gov · Last updated 23 Mar 2026

Brief summary (registry, in English)

This clinical trial aims to evaluate how variations in dietary fat content and hormonal status influence postprandial glycemic response in individuals with type 1 diabetes (T1D), with a special focus on women. The main objective is to clarify the impact of both factors individually and their interaction, which could inform more personalized strategies for insulin adjustment, optimizing glycemic control, and improving patient outcomes. The main objective is to investigate the effects of low-fat versus high-fat meals, sex, menstrual cycle phases, and their interaction on postprandial glycemic control in adults with T1D treated with advanced hybrid closed-loop (AHCL) insulin delivery systems. Specifically, the study will: * Compare postprandial glycemic responses after standardized low and high-fat meals in men and women with T1D. * Assess the differences in postprandial glycemic responses between early follicular and late luteal phases in women, using standardized meals with low and high fat content. * Identify sex-related differences in glycemic response after equivalent meals. This research addresses the unmet clinical need for precise, tailored postprandial insulin dosing recommendations, especially among women whose insulin sensitivity fluctuates with menstrual phases. The results may contribute to sex-specific predictive models in AHCL systems, reducing acute complications and improving overall quality of life. This is a randomized controlled crossover trial in which each participant serves as her/his own control. Fifty adults will be enrolled: 25 women and 25 men. Women will undergo four mixed-meal tests in random order: * low-fat given during the early follicular phase, * high-fat given during the early follicular phase, * low-fat given during the late luteal phase, * high-fat given during the late luteal phase. The menstrual phase will be confirmed with home-based hormonal monitoring devices that function with urine sample and use a single-use test wand (MIRA system). Men will complete two mixed-meal tests (low-fat and high-fat), in randomized order. All meals will be standardized for carbohydrate content and matched in other macronutrients, except for fat (with a 30-40g difference), administered after an 8-hour fast. The day of the mixed meal test, AHCL systems will be switched from automatic to manual mode just before eating to standardize the prandial insulin dose and to avoid differences in insulin infusion rates in the postprandial state due to algorithm compensations. Continuous glucose monitoring (CGM) and hourly capillary glucose testing will measure the postprandial response. Additional fasting blood samples will assess metabolic, hormonal, and lipid markers. Optional gastric emptying studies may be performed to exclude confounding gastroparesis in selected patients. Participants will be recruited from the endocrinology outpatient unit of La Fe Polytechnic University Hospital . The projected recruitment period is from December 2025 to July 2027, with mixed-meal tests and data collection occurring between January 2026 and December 2027. Women are expected to complete the protocol in 6 weeks (4 tests), while men will require about 2 weeks (2 tests). At baseline, participants will undergo blood tests to rule out endocrine disorders and confirm sex hormone status. Women participating in the study will use the MIRA home device to monitor their hormonal levels, allowing them to accurately determine and record the phases of their menstrual cycle as part of the study protocol. During meal tests, CGM (Freestyle Libre 3) will be used uniformly among subjects. The study dependent variables will be the following: * Postprandial glucose area under the curve - AUC\_PG\_5h * Mean glucose level - MG * Continuous glucose monitoring metrics - TIR, TAR, TBR * Postprandial glucose standard deviation - SD * Postprandial glucose coefficient of variation - CV * Mean amplitude of glycemic excursions - MAGE * Mean of daily differences (MODD) Independent variables are * Type of food: Meals with either low or high fat content. * Sex and Hormonal status: men; women during the early follicular phase; women during the late luteal phase. If successful, this study will inform the development of more sophisticated, individualized insulin dosing algorithms and AHCL system improvements, especially for women with T1D. Results may lead to more effective management strategies, reduced GV, lower incidence of complications, and increased quality of life. Insights may directly support the personalization of diabetes care and improve gender equity in treatment standards.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
29 Nov 2025
Start date
May 2026
Primary completion date
Oct 2027
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
NCT number
NCT07278063

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From May 2026 to the primary completion date, Oct 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Presence of hypogonadism, anovulation, hyperandrogenism, hyperprolactinemia, pregnancy, or decompensated chronic diseases.

Lab values

  • Use of oral medications that alter glucose metabolism.

Other

  • Diagnosis of diabetic gastroparesis.

Who the study is looking for

  • Patients with a confirmed diagnosis of type 1 diabetes mellitus for more than 2 years, in treatment with AHCL (Advanced Hybrid Closed Loop) system treatment for at least 6 months.
  • Both sexes.
  • Metabolic control with HbA1c \<8%.
  • BMI between 18.5 and 29.99 (normal weight to overweight).
  • For women: regular menstrual cycles (21-35 days in length with variation between cycles of \<4 days) and no use of hormonal contraceptive treatment.

Age in the registry: 18 years to 45 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital La Fe
Coordinator of this site? Confirm its status
ValenciaSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.